The mechanism underlying the prolonged remission observed in one patient with an exceptional response therefore remains unknown but it is possible that this patient belongs to a small subgroup of AML and ALL patients in which the PI3K pathway functions as oncogenic driver at the level of LSCs. This evidence concerns the gene PIK3CD and acute myeloid leukemia.